Pancreatic Cancer Research

ResearcherUniversität UlmActive in the last 2 years

Benno Traub

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8380-2268; OpenAlex author ID A5010158850. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 2 papers · 2021: 4 papers · 2022: 3 papers · 2023: none · 2024: none · 2025: 1 paper

Papers 11

  1. ARP2/3 complex affects myofibroblast differentiation and migration in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.35246↗
  2. c-Jun N-terminal kinase 2 suppresses pancreatic cancer growth and invasion and is opposed by c-Jun N-terminal kinase 1. First author DOI 10.1038/s41417-020-00290-5↗
  3. JNK inhibitor IX restrains pancreatic cancer through p53 and p21. Last author DOI 10.3389/fonc.2022.1006131↗
  4. Loss of Interleukin-13-Receptor-Alpha-1 Induces Apoptosis and Promotes EMT in Pancreatic Cancer. Last author DOI 10.3390/ijms23073659↗
  5. Curing pancreatic cancer. Co-author DOI 10.1016/j.semcancer.2021.05.030↗
  6. The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises Pancreatic Cancer Cells to TRAIL-induced Cell Death. Last author DOI 10.21873/anticanres.15416↗
  7. Involvement of IL-4, IL-13 and Their Receptors in Pancreatic Cancer. Co-author DOI 10.3390/ijms22062998↗
  8. Stress-activated kinases as therapeutic targets in pancreatic cancer. Co-author DOI 10.3748/wjg.v27.i30.4963↗
  9. Intraductal Transplantation Models of Human Pancreatic Ductal Adenocarcinoma Reveal Progressive Transition of Molecular Subtypes. Co-author DOI 10.1158/2159-8290.cd-20-0133↗
  10. Opposing Oncogenic Functions of p38 Mitogen-activated Protein Kinase Alpha and Beta in Human Pancreatic Cancer Cells. First author DOI 10.21873/anticanres.14567↗
  11. Endogenously Expressed IL-4Rα Promotes the Malignant Phenotype of Human Pancreatic Cancer In Vitro and In Vivo. Co-author DOI 10.3390/ijms18040716↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marko Kornmann · 9 shared papers, 2017–2022 · strength 1.42
  2. Jingwei Shi · 4 shared papers, 2021–2022 · strength 0.67
  3. Xiaodong Tian · 2 shared papers, 2020–2022 · strength 0.28
  4. Helmut Frieß · 1 shared paper, 2025 · strength 0.23
  5. Chao Fang · 1 shared paper, 2025 · strength 0.23
  6. Yifeng Sun · 1 shared paper, 2025 · strength 0.23
  7. Bindhu K. Madhavan · 1 shared paper, 2025 · strength 0.23
  8. Christoph W. Michalski · 1 shared paper, 2025 · strength 0.23
  9. Bo Kong · 1 shared paper, 2025 · strength 0.23
  10. Ingrid Herr · 1 shared paper, 2025 · strength 0.23
  11. Johannes Lemke · 2 shared papers, 2017–2021 · strength 0.23
  12. Joachim Bischof · 1 shared paper, 2021 · strength 0.17
  13. Anna-Laura Kretz · 1 shared paper, 2021 · strength 0.16
  14. Jan-Philipp Ruff · 1 shared paper, 2021 · strength 0.16
  15. Christopher R. Vakoc · 1 shared paper, 2020 · strength 0.08
  16. Lindsey A. Baker · 1 shared paper, 2020 · strength 0.08
  17. Brinda Alagesan · 1 shared paper, 2020 · strength 0.08
  18. Giuseppina Caligiuri · 1 shared paper, 2020 · strength 0.08
  19. Koji Miyabayashi · 1 shared paper, 2020 · strength 0.08
  20. Tim D.D. Somerville · 1 shared paper, 2020 · strength 0.08
  21. Richard Andrew Burkhart · 1 shared paper, 2020 · strength 0.08
  22. Laura DeLong Wood · 1 shared paper, 2020 · strength 0.08
  23. Chang‐Il Hwang · 1 shared paper, 2020 · strength 0.08
  24. Nicholas Jason Roberts · 1 shared paper, 2020 · strength 0.08
  25. Steve Gallinger · 1 shared paper, 2020 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.